SynthesisRadiology. Imaging cancer2021
Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis.
Synthesis in Radiology. Imaging cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Potential role of breast MRI to identify patients with high-risk lesions who might avoid surgery: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Accuracy and Utility of Preoperative Ultrasound-Guided Axillary Lymph Node Biopsy for Invasive Breast Cancer: A Systematic Review and Meta-Analysis.Computational intelligence and neuroscience · 2022Pooled it
- High-Risk Breast Lesions on Core Biopsy: Rates of Upgrade and Management Recommendations.Surgical pathology clinics · 2025Review
- Article
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.Breast care (Basel, Switzerland) · 2025Review
- Malignant upgrade in lesions of uncertain malignant potential in the breast (B3 lesions) - is open excision always necessary?Breast cancer research and treatment · 2025Article
- Navigating the Uncertainty of B3 Breast Lesions: Diagnostic Challenges and Evolving Management Strategies.Journal of personalized medicine · 2025Review
- Assessing Malignant Risk in B3 Breast Lesions: Clinical Insights and Implications.Journal of clinical medicine · 2024Article
- Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.Breast care (Basel, Switzerland) · 2024Review
- Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.Breast care (Basel, Switzerland) · 2023Review
- Outcomes of high-risk breast lesions diagnosed using image-guided core needle biopsy: results from a multicenter retrospective study.Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).Virchows Archiv : an international journal of pathology · 2023Review
- Dimorphic cells: a common feature throughout the low nuclear grade breast neoplasia spectrum.Virchows Archiv : an international journal of pathology · 2023Article
- [B3 lesions of the breast: histological, clinical, and epidemiological aspects : Update].Pathologie (Heidelberg, Germany) · 2023Review
- Prevalence, Impact, and Diagnostic Challenges of Benign Breast Disease: A Narrative Review.International journal of women's health · 2023Review
- Are Columnar Cell Lesions the Earliest Non-Obligate Precursor in the Low-Grade Breast Neoplasia Pathway?Current oncology (Toronto, Ont.) · 2022Review
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.Breast care (Basel, Switzerland) · 2022Review
- Article
- Isolated Flat Epithelial Atypia: Upgrade Outcomes After Multidisciplinary Review-Based Management Using Excision or Imaging Surveillance.Journal of breast imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To perform a systematic review and meta-analysis to calculate the pooled upgrade rate of pure flat epithelial atypia (FEA) diagnosed at core needle biopsy (CNB). Materials and Methods: A PubMed and Embase database search was performed in December 2019. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Study quality and publication bias were assessed. The upgrade rate of pure FEA to cancer, invasive carcinoma, and ductal carcinoma in situ (DCIS), as well as the co-occurrence rate of atypical ductal hyperplasia (ADH), with 95% CIs were calculated. A random effect model was used to integrate the proportions and their corresponding 95% CI. Study heterogeneity was calculated using τ Results: A total of 2482 cases of pure FEA across 42 studies (mean age range, 46-59 years) met inclusion criteria to be analyzed. Significant study heterogeneity was identified (τ Conclusion: Pure FEA diagnosed at CNB should be surgically excised due to the pooled upgrade rate of 5% for breast cancer. If more than 90% of the targeted calcifications are removed by CNB for pure FEA, close imaging follow-up is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.